Chase AIPricingFAQs
Display currency
Loading news…

Lutris Pharma

ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals.
Tel Aviv-yafo, Tel Aviv, Israel Founded 2015 11-50 employees For Profit

Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.

Total Funding
Available in Pro
Last Funding
Available in Pro
Acquisitions
0
Monthly Visits
Available in Pro
Contacts
1
Patents
13

Company Details

Funding & Financials

Pro
Total funding
Funding rounds
Last funding
Last funding type
Last funding date
Funding status
Total equity funding
Revenue range

IPO & Stock

IPO status
Private

Web Traffic

Pro
Monthly visits
Global traffic rank
6-mo avg visits
Visit duration (s)
Pages / visit
Bounce rate
Rank change (mo)

Technology & IP

Active technologies
2
Patents granted
13
Trademarks
0
Top patent class
Medical Or Veterinary Science; Hygiene
IT spend
$9M

Company Info

Founded
2015
Employees
11-50
Operating status
Active
Company type
For Profit
Org types
company
Founders
1
News articles
22
HQ
Tel Aviv-yafo, Tel Aviv, Israel
Region
Europe, Middle East, and Africa (EMEA), Middle East, Middle East and North Africa (MENA)

Signals & Scores

Heat score
Medium
Growth score
Low
Trend (7d)
-0.1
Trend (30d)
-0.1
Trend (90d)
-0.1

Key People at Lutris Pharma

Founder & CEO
1
professional contacts at Lutris Pharma
Contact execs at Lutris Pharma

Explore 200,000+ acquisitions — free

Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.

Explore all acquisitions

Recent News related to Lutris Pharma

Loading news…

FAQs about Lutris Pharma

People who checked this page also checked these

Browse the full Acquirezy directory.
Lutris Pharma - Company Profile, Full Acquisitions List, Funding and Investments